BriaCell Raises $4.7M Through 1.45M-Share Offering at $3.25 Each
BCTX•BriaCell Therapeutics sold 1,449,300 common shares at $3.25 each in a best-efforts offering, raising approximately $4.7 million in gross proceeds. The company plans to use net proceeds for working capital, general corporate purposes and to advance its clinical-stage immunotherapies for cancer.
1. Offering Structure
BriaCell closed a best-efforts offering of 1,449,300 common shares at an offering price of $3.25 per share, generating gross proceeds of approximately $4.7 million before fees and expenses.
2. Use of Proceeds
The company intends to apply net proceeds toward working capital requirements, general corporate purposes and the advancement of its clinical-stage immuno-oncology programs targeting cancer treatment.
3. Regulatory and Placement Agent
The offering was conducted under a Form S-3 shelf registration and relied on Section 602.1 TSX exemption for interlisted issuers, with ThinkEquity acting as sole placement agent.
4. Company Profile
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies designed to transform the management and outcomes of cancer care.
